← All trials
NCT03950518
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 10, 2019
- Primary completion
- Apr 10, 2023
- Completion date
- Apr 10, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhengzhou UniversityLead sponsor
- Zhengzhou UniversityReponsible party - principal investigator
- Anyang Regional HospitalCollaborator
- Nanyang Central HospitalCollaborator
- Luoyang Central HospitalCollaborator
- The Third People's Hospital of JiaozuoCollaborator
- Sanmenxia Central HospitalCollaborator
- Pingdingshan Coal Medical Group General HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.